INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25501, 12268, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25502, 12271, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25503, 12272, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25504, 12298, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25505, 12299, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25506, 13601, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25507, 14113, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25508, 18058, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25509, 18513, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25510, 18759, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25511, 23416, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25512, 23417, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25513, 23420, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25514, 24262, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25515, 24912, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25516, 25917, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25517, 26556, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25518, 26957, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25519, 26959, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25520, 26962, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25521, 26963, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25522, 26985, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25523, 27525, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25524, 29208, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25525, 29209, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25526, 29210, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25527, 29222, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25528, 29227, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25529, 29295, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25530, 29303, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25531, 29305, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25532, 29398, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25533, 30424, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25534, 32121, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25535, 32127, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25536, 32147, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25537, 33250, 'Sildenafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25538, 25810, 'Sevelamer', 'Gastrointestinal Diseases', 'Sevelamer is contraindicated in patients with bowel obstruction.  Cases of bowel obstruction and perforation have been reported with the use of sevelamer.  Care and appropriate measures should be taken if patients develop constipation or worsening of existing constipation while on sevelamer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25539, 25866, 'Sevelamer', 'Gastrointestinal Diseases', 'Sevelamer is contraindicated in patients with bowel obstruction.  Cases of bowel obstruction and perforation have been reported with the use of sevelamer.  Care and appropriate measures should be taken if patients develop constipation or worsening of existing constipation while on sevelamer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25540, 26885, 'Sevelamer', 'Gastrointestinal Diseases', 'Sevelamer is contraindicated in patients with bowel obstruction.  Cases of bowel obstruction and perforation have been reported with the use of sevelamer.  Care and appropriate measures should be taken if patients develop constipation or worsening of existing constipation while on sevelamer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25541, 31198, 'Sevelamer', 'Gastrointestinal Diseases', 'Sevelamer is contraindicated in patients with bowel obstruction.  Cases of bowel obstruction and perforation have been reported with the use of sevelamer.  Care and appropriate measures should be taken if patients develop constipation or worsening of existing constipation while on sevelamer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25542, 25810, 'Sevelamer', 'Deglutition Disorders', 'Cases of dysphagia and esophageal tablet retention have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention.  Consider using sevelamer suspension in patients with a history of swallowing disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25543, 25866, 'Sevelamer', 'Deglutition Disorders', 'Cases of dysphagia and esophageal tablet retention have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention.  Consider using sevelamer suspension in patients with a history of swallowing disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25544, 26885, 'Sevelamer', 'Deglutition Disorders', 'Cases of dysphagia and esophageal tablet retention have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention.  Consider using sevelamer suspension in patients with a history of swallowing disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25545, 31198, 'Sevelamer', 'Deglutition Disorders', 'Cases of dysphagia and esophageal tablet retention have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention.  Consider using sevelamer suspension in patients with a history of swallowing disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25546, 25810, 'Sevelamer', 'Kidney Diseases', 'Patients on peritoneal dialysis should be closely monitored to ensure the reliable use of appropriate aseptic technique with the prompt recognition and management of any signs and symptoms associated with peritonitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25547, 25866, 'Sevelamer', 'Kidney Diseases', 'Patients on peritoneal dialysis should be closely monitored to ensure the reliable use of appropriate aseptic technique with the prompt recognition and management of any signs and symptoms associated with peritonitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25548, 26885, 'Sevelamer', 'Kidney Diseases', 'Patients on peritoneal dialysis should be closely monitored to ensure the reliable use of appropriate aseptic technique with the prompt recognition and management of any signs and symptoms associated with peritonitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25549, 31198, 'Sevelamer', 'Kidney Diseases', 'Patients on peritoneal dialysis should be closely monitored to ensure the reliable use of appropriate aseptic technique with the prompt recognition and management of any signs and symptoms associated with peritonitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25550, 28797, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25551, 28798, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25552, 28799, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25553, 28800, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25554, 28801, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25555, 28802, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25556, 28803, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25557, 28804, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25558, 28805, 'Selexipag', 'Liver Failure', 'Liver impairment can increase exposure to selexipag and its metabolites.  No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment.  There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25559, 28797, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25560, 28798, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25561, 28799, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25562, 28800, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25563, 28801, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25564, 28802, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25565, 28803, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25566, 28804, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25567, 28805, 'Selexipag', 'Kidney Diseases', 'No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2.  There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25568, 0, 'Siltuximab', 'Infections', 'There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors.  Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated.  Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25569, 0, 'Siltuximab', 'Peptic Ulcer Perforation', 'The use of siltuximab may cause gastrointestinal (GI) perforation.  Use with caution in patients who may be at increased risk for GI perforation.  It is recommended to closely monitor patients for symptoms indicative or that may be associated with GI perforation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25570, 0, 'Siltuximab', 'Liver Diseases', 'Based on a population pharmacokinetic analysis using data from clinical trials in patients, no significant difference in siltuximab clearance was observed in patients with preexisting mild to moderate hepatic impairment (Child-Pugh Class A and B, respectively) compared to patients with baseline normal hepatic function.  No initial dosage adjustment is necessary for patients with mild to moderate hepatic impairment.  Care should be taken when using this agent in patients with baseline severe hepatic impairment (Child-Pugh Class C) as the potential effect on siltuximab pharmacokinetics cannot be determined as clinical and pharmacokinetic data are not available.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25571, 0, 'Siltuximab', 'Kidney Diseases', 'Based on a population pharmacokinetic analysis using data from clinical trials in patients, no significant difference in siltuximab clearance was observed in patients with preexisting renal impairment (creatinine clearance (CrCl) >=15 mL/min) compared to patients with baseline normal renal function (CrCl)>= 90 mL/min).  No initial dosage adjustment is necessary for patients with CrCl >= 15 mL/min.  Care should be taken when using this agent in patients with end-stage renal disease as the potential effect on siltuximab pharmacokinetics cannot be determined.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25572, 6304, 'Selumetinib', 'Cardiomyopathies', 'Cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF) >=10% below baseline, occurred in over 20% of pediatric patients who received selumetinib.  The safety of this drug has not been established in patients with a history of impaired LVEF or an ejection fraction below the limit of normal.  Caution is advised if using on these patients.  Assess ejection fraction by echocardiogram prior to initiating treatment, and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25573, 6305, 'Selumetinib', 'Cardiomyopathies', 'Cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF) >=10% below baseline, occurred in over 20% of pediatric patients who received selumetinib.  The safety of this drug has not been established in patients with a history of impaired LVEF or an ejection fraction below the limit of normal.  Caution is advised if using on these patients.  Assess ejection fraction by echocardiogram prior to initiating treatment, and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25574, 6304, 'Selumetinib', 'Hepatic Insufficiency', 'Selumetinib exposure is increased in patients with moderate or severe hepatic impairment.  A recommended dosage has not been established for patients with severe hepatic impairment (Child-Pugh C), and a dose reduction is required in patients with moderate hepatic impairment (Child-Pugh B).  Caution is advised when using in patients with these levels of hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25575, 6305, 'Selumetinib', 'Hepatic Insufficiency', 'Selumetinib exposure is increased in patients with moderate or severe hepatic impairment.  A recommended dosage has not been established for patients with severe hepatic impairment (Child-Pugh C), and a dose reduction is required in patients with moderate hepatic impairment (Child-Pugh B).  Caution is advised when using in patients with these levels of hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25576, 4799, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25577, 16723, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25578, 16724, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25579, 18172, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25580, 19150, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25581, 19151, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25582, 21814, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25583, 26093, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25584, 26964, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25585, 26965, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25586, 26976, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25587, 27803, 'Silodosin', 'Hepatic Insufficiency', 'The use of silodosin is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25588, 4799, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25589, 16723, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25590, 16724, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25591, 18172, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25592, 19150, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25593, 19151, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25594, 21814, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25595, 26093, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25596, 26964, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25597, 26965, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25598, 26976, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25599, 27803, 'Silodosin', 'Kidney Failure, Chronic', 'The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min).  Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function.  Dose should be reduced to 4 mg/day in patients with moderate renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25600, 4799, 'Silodosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', '', 'DDInter', 0);
